Ikano Therapeutics
Acquired by UCB
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.
Investment Team
Sector
Life SciencesCategory
TherapeuticsLocation
Montvale, NJInitial Investment
2006
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.
Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.